Clinical Trial Search

Primary: Number of Participants With Grade 3-5 National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE V5) Bleeding/Haemorrhage — 17; 3…

Primary: Average Change in Subjective Pain Level Using a 10 Point Likert Scale — -0.72; 0.61 pain score

Primary: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, Y, and W — 72.1; 100…

Primary: Blood Oxygen Level Dependent (BOLD) Brain Signal Measured Using Functional MRI. — 270; 111 voxels — p=<0.0001

Primary: Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 59457.92; 46951.21…

Primary: Mean Difference in Borg Category Rating Scale Before and After 6MWT at 2 Weeks — 3.4; 2.8; 3.1; 2.5 score on a scale

Primary: Change From Baseline in AN Count at Week 16: Placebo-Controlled Period — -5.9; -4.1; -5.6 count of abscess and inflammatory nodule — p=0.7841

Primary: Number of Participants From Randomization to First Occurrence of a Major Adverse Cardiovascular Event (MACE), a Composite Endpoint Consisting of: Cardiovascular (CV)…

Primary: Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI — 3.90; 2.08; 3.64; 1.74 mean of a score (on a scale) per patient — p=<.0001

Primary: Cure Rate (CR) Against T. Trichiura — 17.5; 50.0; 83.3; 84.6 percentage of participants cured (%)

Primary: Walking Speed Change From Baseline — 0.033; 0.041 meters per second

Primary: Change in WAB-AQ — 3.0; 2.8 score on a scale — p=<.05

Primary: Percentage of Screened Participants Who Screen Eligible for the Study — 65.22 percentage of participants

Primary: Number of Participants With A Minimum of One Grade Improvement in the Standard Submental Fat (SMF) Assessment Grading — 15; 10 Participants

Primary: Number and Percentage of Participants With Serious Adverse Events — 15; 12; 265; 266 Participants